Clinical Trials
13 trialsNCT05579366 2026-05-26
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT03564340 2026-05-08
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05417594 2026-05-05
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05739981 2026-05-04
MRD
Imunon
Phase 1/2 Recruiting
NCT05985655 2026-04-23
ELUCIDATE
Exscientia AI Limited
Phase 1/2 Recruiting
NCT05920798 2026-04-06
FRAPPE
Mayo Clinic
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT07480954 2026-03-18
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT07460180 2026-03-10
PROOV
The Netherlands Cancer Institute
Phase 1/2 Recruiting
NCT07322094 2026-01-07
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL Biotherapeutics, LLC
Phase 1/2 Recruiting
NCT04590326 2025-11-21
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05086692 2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2 Recruiting